Published data reveals new mechanism to inhibit oligomers, key driver of Alzheimer's

(The Yates Network) Peer-reviewed results published in the journal CNS Drugs elucidate a new molecular mechanism of action for tramiprosate, the active agent in Alzheon's Phase 3-ready drug candidate, ALZ-801. Scientists discovered that tramiprosate blocks production of neurotoxic beta amyloid oligomers by 'enveloping' the A ß 42 amyloid peptide, and prevents its misfolding and aggregation. This enveloping prevents the self-assembly of misfolded amyloid monomers into toxic oligomers that cause neurotoxicity and clinical progression in patients with Alzheimer's disease.
Source: EurekAlert! - Biology - Category: Biology Source Type: news